🔗 Share this article

As the United States proceeds with sweeping adjustments to its vaccine guidelines, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by questioning Covid vaccines in the pandemic and has concentrated on potential deaths after COVID-19 immunization in her recent position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Program

Health officials were set to reveal major changes to the childhood immunization program recently, aligning the US with Denmark’s vaccine program, according to reports – a major change that would place the US out of step with a large portion of the world with insufficient data for public health gain. The planned update has been pushed back until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was recently named interim head of the FDA’s CDER, the fifth appointee to head the office this year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing some pediatric shot schedules in the US to become more in line with Denmark's approach, a society with comprehensive healthcare and a citizenry approximately the size of Wisconsin’s.

To date statements, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Doubts Over Qualifications

Høeg has little discernible background in drug development, regulation or management, which has been typical for previous directors of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She has no expertise in running a major agency. She has no expertise in industry regulation.”

Former heads of CBER would “understand laws and regulations and the underlying principles of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who ran the center have had.”

CDER has an immense range of responsibilities at the agency, the former commissioner pointed out.

“Many people just pays attention on the innovative therapies, but the generic drug division approves thousands of generic medications. There’s a biosimilars program, over-the-counter program and other areas, and each of these must be managed,” she noted. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

There is also, a major management component to the job, which supervises in excess of 5,000 personnel. “It is a huge management job, if you do it right,” the former official added.

Response and Disputed Policies

When asked about inquiries about Dr. Høeg's credentials and whether this selection indicates increased cooperation among regulatory chiefs on immunizations, a representative said that the “questions are based on inaccurate premises”.

“This background aligns with the functions of her role,” the representative explained, noting the period Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed one-day medication authorization process that apparently troubled her predecessors. “By what process are these therapies being chosen for this expedited pathway? Who takes the calls?” Howard asked. “There’s a lot of confidentiality occurring at the FDA right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of pharmaceuticals, except for immunizations.”

Established History on Vaccines

Regarding immunizations, Høeg has a more established, if problematic, history, critics said. She authored a analysis using unverified volunteer-provided data to determine the frequency of myocarditis after Covid vaccination. She counseled the Florida top health official Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are riskier than they are.

Among her “wish list” for the new administration included altering guidelines for new vaccines and discontinuing “non-essential” vaccines, she remarked after the election on a online show. At the agency, Dr. Høeg has allegedly proposed preventing teenage boys from getting Covid vaccines.

“She is an thorough dogmatist who begins with her preconceived notions and tailors the evidence to fit the data in a very misleading, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of other dissenters, {like|